Hair shedding after menopause is scary enough without wondering whether testosterone will make it worse.
The answer is narrower than the internet usually makes it. Trials of transdermal testosterone for postmenopausal women with hypoactive sexual desire disorder did not show a clear alopecia increase versus placebo. They did show more androgenic side effects. [3]
That means the right question is not "Does testosterone usually cause hair loss?" The better question is more clinical. Is this ordinary female pattern hair loss, shedding from another cause, too-high androgen exposure, or a red flag?
Does testosterone therapy cause hair loss after menopause?
A systematic review of transdermal testosterone for postmenopausal women with hypoactive sexual desire disorder included seven randomized trials and 3,035 participants. It compared 1,350 women assigned to testosterone patch with 1,379 assigned to placebo. [3]
The testosterone group had more satisfying sexual episodes, sexual activity, orgasms, desire, and lower distress. It also had more androgenic adverse events, acne, and increased hair growth. [3]
But the same analysis found no significant difference for facial hair, alopecia, voice deepening, urinary symptoms, breast pain, headache, total adverse events, serious adverse events, withdrawals, or completion. [3]
That does not establish hair loss is impossible. It says alopecia was not a clear excess signal in those trials at studied doses and durations.
Why do guidelines still make dose and monitoring central?
The Global Consensus Position Statement says the only evidence-based indication for testosterone therapy in women is hypoactive sexual desire disorder after formal assessment. [1]
The International Society for the Study of Women's Sexual Health guideline gives practical prescribing and monitoring guidance for systemic testosterone in women with hypoactive sexual desire disorder. It emphasizes patient selection, lab testing, dosing, follow-up, and avoiding too-high levels. [2]
This is where hair concerns belong. If prescription testosterone is being used, the clinician should know the product, dose, amount applied, blood level, timing of the blood draw, symptoms, acne changes, hirsutism, scalp pattern, and whether dehydroepiandrosterone or other androgenic products are also in use.
Why does hair loss need its own diagnosis?
Female pattern hair loss is common and can be distressing. A Cochrane review found 47 randomized trials covering 5,290 participants for female pattern hair loss, but only five were judged at low risk of bias. [5]
That evidence picture matters because "hair loss" is not one diagnosis. A widening part, diffuse shedding after rapid weight loss, iron deficiency, thyroid disease, scalp inflammation, medication-related shedding, and androgen excess can look similar to a patient.
An Androgen Excess and polycystic ovary syndrome Society report on female pattern hair loss also emphasizes that possible androgen excess should be assessed, because androgen-sensitive hair patterns can overlap with hirsutism, acne, irregular bleeding history, polycystic ovary syndrome, or ovarian/adrenal sources. [6]
Testosterone review should not replace dermatology-style hair triage. It should sit inside it.
| Hair-loss clue | More likely first review |
|---|---|
| Gradual widening part without scalp pain | Female pattern hair loss and minoxidil discussion. |
| Sudden shedding after illness, surgery, rapid weight loss, or calorie restriction | Telogen effluvium trigger review before changing testosterone. |
| Itch, scale, pustules, pain, or scarring | Scalp disease or scarring alopecia evaluation. |
| Hair loss plus acne or unwanted facial hair | Androgen exposure, polycystic ovary syndrome history, or androgen-excess workup. |
| Hair loss after a dose increase or new androgenic product | Product, dose, timing, blood level, and stop-rule review. |
When is androgen excess the red-flag category?
Postmenopausal androgen excess is different from ordinary hair thinning. A 2023 clinical review describes hirsutism as the most effective sign of androgen excess in women. Symptoms can also include acne, androgenic alopecia, and virilization such as clitoromegaly. [4]
The same review states that testosterone above 5 nmol/L is linked with virilization and needs prompt investigation for an androgen-producing tumor. [4]
In plain language, rapid hair loss with new coarse facial hair, acne, voice deepening, clitoromegaly, or very high testosterone is not a cosmetic side effect to manage casually. It is a diagnostic signal.
| Hair or androgen pattern | Safer decision route |
|---|---|
| Gradual widening part | Could be female pattern hair loss; testosterone exposure is only one piece of the review. |
| Diffuse shedding after illness, surgery, stress, or weight loss | Consider telogen effluvium and trigger history before blaming testosterone. |
| New acne or unwanted facial hair after starting testosterone | Review dose, product, application, blood level, and other androgenic products. |
| Rapid scalp thinning with virilization signs | Treat as a prompt androgen-excess evaluation, not routine hair care. |
| Pain, scale, pustules, or scarring | Consider inflammatory or scarring scalp disease that needs dermatology review. |
Who testosterone review fits, and who should avoid or slow down
The right next step is not fear-based avoidance of testosterone. It is measured eligibility and monitoring.
A good clinical intake should separate hypoactive sexual desire disorder from fatigue, mood symptoms, vaginal dryness, relationship pain, medicine effects, and sleep problems. If prescription testosterone is appropriate, it should also set baseline levels and side-effect monitoring.
Testosterone review may fit when low desire with distress remains after that assessment and hair loss has a separate pattern review. It is a poor fit for self-escalation, pellets, supraphysiologic dosing, or ignoring new androgenic effects. Anyone with rapid scalp loss plus acne, hirsutism, voice change, clitoral symptoms, or very high testosterone should avoid routine dose continuation until androgen excess is evaluated.
For the reader, the practical takeaway is specific: hair loss does not automatically rule out testosterone therapy, and testosterone therapy does not excuse ignoring hair-loss red flags.
What to ask your clinician
- Does my hair loss pattern look like female pattern hair loss, diffuse shedding, scalp inflammation, scarring alopecia, or androgen excess?
- If I use prescription testosterone, what product, dose, application site, and blood-test timing keep exposure in the intended female range?
- Are acne, facial hair, voice change, clitoromegaly, or rapid scalp change present enough to require hyperandrogenism testing?
- Should dehydroepiandrosterone, compounded hormones, pellets, or other androgenic products be stopped or reviewed before interpreting labs?
- Which hair findings should lead to dermatology review rather than hormone adjustment?
Bottom line
Physiologic-dose testosterone for carefully diagnosed hypoactive sexual desire disorder has not shown a clear alopecia signal in the cited patch trials, but hair loss after menopause still deserves its own diagnosis. The safest path is to separate female pattern loss, shedding triggers, scalp disease, and androgen excess before blaming or escalating testosterone.
How the assessment helps
A structured assessment can organize testosterone product and dose, timing of hair changes, acne or facial hair, voice or clitoral symptoms, scalp pattern, rapid weight loss, thyroid or iron clues, dehydroepiandrosterone or pellet exposure, and blood-test timing so a clinician can decide whether this is hair-loss triage, androgen-excess review, or testosterone monitoring. It is not a hair-loss diagnosis by itself.
Related reading:
- Testosterone Side Effects in Women After Menopause.
- Testosterone and Heart Risk in Women.
- Testosterone and Vaginal Dryness After Menopause.
- Testosterone Blood Tests After Menopause.
References
[1] Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429-434. doi:10.1080/13697137.2019.1637079 https://pubmed.ncbi.nlm.nih.gov/31474158/
[2] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2020.10.009 https://pubmed.ncbi.nlm.nih.gov/33814355/
[3] Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril. 2017;107(2):475-482.e15. doi:10.1016/j.fertnstert.2016.10.028 https://pubmed.ncbi.nlm.nih.gov/27916205/
[4] Hirschberg AL. Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman. J Clin Endocrinol Metab. 2023;108(5):1243-1253. doi:10.1210/clinem/dgac673 https://pubmed.ncbi.nlm.nih.gov/36409990/
[5] van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016;2016(5):CD007628. doi:10.1002/14651858.cd007628.pub4 https://pubmed.ncbi.nlm.nih.gov/27225981/
[6] Carmina E, Azziz R, Bergfeld W, et al. Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. J Clin Endocrinol Metab. 2019;104(7):2875-2891. doi:10.1210/jc.2018-02548 https://pubmed.ncbi.nlm.nih.gov/30785992/